the TAMI Study Group* Two dosing schedules of intravenous tissue plasminogen activator (t-PA) for acute myocardial infarction were compared in a multicenter trial. At 2.95 f 1.1 hours from onset of chest pain, 388 patients received 150 mg of intravenous t-PA. For the first 178 patients (group A), 80 mg were given in the first-hour dose and the remaining 90 mg were infused over 7 hours. In the subsequent 208 patients (group B), the first-hour dose was 1.0 mg/kg and the remaining 150 mg were given over 5 hours. At initial angiography 94 f 30 minutes into therapy, the infarct vessel patency was 84% in group A versus 75% in group B (p = 0.02). By final angiography with up to 4 selective contrast injections, patency was 88 % versus 77 % , respectively (p = 0.08). Repeat angiography at 7 to IO days demonstrated reocclusion in 17 % of group A and 13 % of group B patients (p = 0.35). There was no difference in fibrinogen nadir or mean hematocrit drop between the 2 groups: 120 mg/dl and 11 points, respectively, in group A compared with 120 mg/dl and 10 points in group B. However, bleeding was reduced in group B patients as evident by a decrease in requirement for 22 units of packed red blood cell transfusion (group A 38 % , group B 27 % , p = 0.05) and lower incidence of gastrointestinal bleeding (group A 12%, group B 4%, p = 0.002). To further study the importance of weight adjustment, patients were divided into 2 groups according to weight (<go kg versus >gO kg). According to the results, lighter weight patients had greater transfusion requirements (35% versus 20%, p = 0.008) and more frequent major bleeding episodes (18% versus 7 % , p = 0.025). Thus, a higher, weight-adjusted first-hour dose of intravenous t-PA, with a shorter duration of maintenance infusion, is associated with: (1) improved infarct vessel patency; (2) more rapid recanalization; and (3) cant change in production methods. Although very low doses of intravenous t-PA were initially used for a brief duration (1 to 3 hours),l-4 more recent trials have employed a larger first-hour dose and a prolonged maintenance infusion.5r6 The initial studies used a predominant z-chain form of t-PA which was not suitable for iarge-scale production. The single-chain form oft-PA subsequently introduced has a clearance 40% more rapid than the original preparation and thereby has required a new pharmacologic evaluation for optimal dosing.5 Although high doses of this form of intravenous t-PA were demonstrated to promote rapid recanalization7 they were associated with an increased rate of serious hemorrhagic episodes which led to a recommendation for a decreased dose.8rg Thus, controversy exists as to the optimal dosing of this fibrinolytic enzyme for achieving maximal coronary thrombolytic 723
cant change in production methods. Although very low doses of intravenous t-PA were initially used for a brief duration (1 to 3 hours),l-4 more recent trials have employed a larger first-hour dose and a prolonged maintenance infusion.5r6 The initial studies used a predominant z-chain form of t-PA which was not suitable for iarge-scale production. The single-chain form oft-PA subsequently introduced has a clearance 40% more rapid than the original preparation and thereby has required a new pharmacologic evaluation for optimal dosing.5 Although high doses of this form of intravenous t-PA were demonstrated to promote rapid recanalization7 they were associated with an increased rate of serious hemorrhagic episodes which led to a recommendation for a decreased dose.8rg Thus, controversy exists as to the optimal dosing of this fibrinolytic enzyme for achieving maximal coronary thrombolytic 723 efficacy with the least possible rate of bleeding complications. The present study was undertaken to determine which of 2 t-PA dosing regimens employed in a multicenter trial was superior in terms of frequency and speed of coronary artery recanalization, effects on hemostasis and the coagulation system, and the importance of weight adjustment.
Methods
The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI] study design has been previously described in detaillo To summarize, selection criteria were: (1) patients with 14 hours of chest discomfort or severe symptoms with a duration of 4 to 6 hours, and ongoing pain; and (2) at least 1 mm of electrocardiographic ST-segment elevation in 2 contiguous leads. Patients were excluded for age >75, recent (<6 months] trauma, surgery or stroke, prolonged cardiopulmonary resuscitation, prior coronary artery bypass grafting, cardiogenic shock and previous transmural infarction in the same area. All patients provided informed consent and the protocol was approved by the institutional review board at the respective clinical site.
In the trial, the predominantly single-chain form of t-PA was used.5 The first 178 patients received an intravenous t-PA dose based on schedule A: 60 mg in the first hour given as a 6-mg bolus and 54-mg drip, and then 20 mg for each of 2 hours, followed by 10 mg/hr for 5 hours with a total dose of 150 mg. In the subsequent 208 patients (schedule B], the same total dose of 150 mg was administered using weight adjustment and a briefer maintenance infusion as follows: 1 mg/kg for the first hour with 10% as a bolus and a maximum dose of 90 mg, and the remainder of 150 mg over the next 5 hours. The patient's report provided the information on body weight required for dosing. The dose regimens are summarized in Table I .
After initiation of t-PA, the patients were transferred to the cardiac catheterization laboratory of the respective clinical site for acute angiography. Nonionic contrast dye was used. The first contrast injection of the infarct vessel was performed after 60 minutes of therapy and images obtained no later than 90 minutes. An exception to the latter occurred when difficulties arose in obtaining arterial access or interhospital transport was delayed. The final determination of infarct vessel patency was made at 90 minutes, after up to 4 injections of the infarct-related artery.
The perfusion status was classified according to the TIM1 (Thrombolysis in Myocardial Infarction Study Group) grading systemn2 For the purpose of this study, TIM1 0 and 1 were considered occluded and TIM1 2 or 3 patent. The angiograms were subsequently reviewed at the core angiographic laboratory for verification of the final TIM1 grade determination.
On the basis of the go-minute infarct vessel angiogram, patients were triaged to 3 different groups as follows: (1) persistent occlusion-coronary angioplasty was considered at the discretion of the investigator; (2) patent, 150% residual stenosis, suitable for angioplasty-patients were randomized to undergo the procedure immediately or at 7 days; (3) patent, with coronary anatomy unsuitable for angioplasty. Emergency coronary artery bypass surgery was defined as a direct transfer from the cardiac catheterization laboratory during the acute study to the operating room. The procedure was performed for failed percutaneous transluminal coronary angioplasty or high-risk coronary anatomy. In the first 50 patients from the aforementioned groups 1 and 3, only the first 3 hours of t-PA (100 mg] were infused (all in group A patients). Angioplasty's complete success was defined as X50% residual stenosis and partial success as 150% residual stenosis after balloon dilatation.
Concomitant medical therapy consisted of heparin (5,000 U at access, 5,000 U at the time of angioplasty if performed acutely, and 500 to 1,000 U/hr for L3 days by continuous infusion adjusted to 2.5 to 3 times the partial thromboplastin time], aspirin (325 mg/day], dipyridamole (75 mg, 3 times daily] and diltiazem (30 to 60 mg, 4 times daily].
At 7 to 10 days, patients underwent repeat cardiac catheterization to determine infarct vessel patency and left ventriculography. Besides the paired studies, patients returned to the catheterization laboratory be-fore 7 days had elapsed if recurrent ischemia occurred, as defined by 120 minutes of chest discomfort associated with electrocardiographic changes. After urgent angiography in these patients, who by now had reached a clinical endpoint, either coronary angioplasty or bypass surgery was performed and followed by a repeat (third] cardiac catheterization, whenever possible, before hospital discharge. Reocclusion was defined by angiographic documentation of flow pattern as TIM1 grade 0 or 1 and flow pattern diagnosed subsequent to established perfusion as TIM1 2 or 3.2
Bleeding complications were characterized according to: (1) site; (2) need for transfusion of 12 units of packed red blood cells for augmentation of hematocrit >3O; and (3) baseline and nadir hematocrit values. Gastrointestinal bleeding referred to either guaiacpositive results or frank blood in emesis or stool. Intracranial and retroperitoneal hemorrhage was diagnosed using computed axial tomographic scanning. Assessment of coagulation proteins included assay of the serum fibrinogen by the Clauss and sodium sulfite precipitation methods11J2 and the fibrinogen degradation product titer I3 by tanned red cell agglutination method at baseline, 3, 8 and 12 hours afl:er t-PA.
Statistical analysis: Values are expressed as mean f 1 standard deviation unless otherwise specified. Comparison of group A versus group B patients was made using chi-square analysis for dichotomous variables and an unpaired t test or Wilcoxon log-rank test, as specified, for continuous variables. The comparison between the 2 dose regimens was performed with and without those 50 patients in group A who received 100 mg instead of 150 mg of t-PA. For analysis of the importance of weight (190 or >90 kg], chi-square analysis was used for dichotomous variables, a Wilcoxon ranksum test for continuous variables and a logistic regression model for testing the relation between the 2 weight groups for multiple variables.
Results
Study population: The relevant demographic characteristics for the 2 patient groups are summarized in Table II . Patients receiving the 2 different dose regimens were similar with regard to the baseline hemodynamic, angiographic and demographic features.
Patency of the infarct vessel: Table III lists the results for acute and follow-up (before discharge) infarct vessel perfusion status. A significantly higher patency was demonstrated for group B patients at the initial angiogram. As demonstrated in Figure 1 , nearly all patients in group B who demonstrated infarct vessel recanalization were already patent at the initial angiogram. The residual stenosis of the infarct vessel was significantly decreased in group B patients compared with group A (Figure 2) . The results for initial angiographic patency excluding the 50 patients in group A who did not receive the full 150 mg t-PA dose were: group A, 68% patent; group B, 75% patent; p = 0. 16. Acute coronary angioplasty was performed in 89 patients in group A and 93 patients in group B with complete or partial success in 73% versus 83%) respectively (p = 0.09). Emergency bypass surgery was necessary in 8% of group A patients compared to 4% in group B (p = 0.09). During hospitalization, a total of 39 (22%] bypass surgery procedures were performed in group A compared with 44 (21%) in group B (p = 0.19). Intraaortic balloon counterpulsation was used in 11% of group A versus 6% of group B patients (p = 0.09).
Bleeding complications and coagulation system effects: The transfusion requirement, admission and nadir hematocrits, and incidence of bleeding by site appear in Table IV . As shown, the frequency of gastrointestinal bleeding was significantly higher in group A patients. Only 2 patients (both in group B) developed intracranial hemorrhage. Both patients were female with a history of longstanding hypertension, age 68 and 73, respectively.
In Figure 3 , the serum fibrinogen values are plotted for the 2 dosage regimens. There was no difference in the nadir fibrinogen level (120 mg/dl for both groups). The median peak FDP titer was 1:16 in group A versus 1:32 for group B.
Influence of body weight: Patients were divided into 2 groups as shown in Table V . The baseline weight was not recorded in 5 patients enrolled in the trial. As expected, there was a significantly lower proportion of males in the 190-kg weight column. There were no differences (p <0.05] in patency of the infarct vessel, infarct location, presence of multivessel disease, group A or B dosing or bypass surgery. Lighter weight patients underwent acute coronary angioplasty less fre- quently (45 versus 58%, respectively, p = 0.0231 and had a higher success rate for angioplasty (84 versus 68%, p = 0.06).
Despite less invasive procedures performed in the lighter weight patient group (equivalent to a 21% bypass surgery rate during hospitalization, less acute angioplasty], their transfusion requirement was higher, with major bleeding episodes more frequent as confirmed by a significantly lower nadir hematocrit (Table V]. In addition, these patients had a lower nadir plasma fibrinogen and a decreased likelihood of reocelusion.
Discussion
In the current study, 2 different t-PA dose regimens with the same 150 mg cumulative dose were compared. The second regimen, which provided for a weight-adjusted first-hour dose and a lesser duration of maintenance infusion, was found to be superior with respect to frequency and rapidity of infarct vessel patency, decreased transfusion requirement and overall bleeding complications, without more extensive fibrinogenopenia.
Comparison with previous studies: There have been 3 previous trials using the single-chain preparation of t-PA. In the randomized trial of Top01 et al5 0.75 mg/kg of t-PA was given over the first hour and 0.25 mg/kg per hour over the subsequent 2 hours. Infarct vessel patency at 90 minutes was 69% and increased to 79% at 120 minutes. Using criteria for bleeding complications similar to those adopted in the current study, 29% received transfusion, gastrointestinal bleeding occurred in l.l%, genitourinary bleeding in 5% and the fibrinogen nadir was 62% of baseline. Reocclusion was not systematically determined but the angiographically confirmed incidence was 20%. As recently reported by Mueller et a1,7 the open-label Thrombolysis in Myocardial Infarction (TIMI) multicenter trial was divided into 5 separate groups [A through E). In the E phase, 167 patients received a dose of 90 mg over the first hour and 60 mg over the subsequent 4 hours. A high rate of infarct vessel patency resulted (85% at 120 min), albeit accompanied by a 1.6% incidence of intracranial hemorrhage. This resulted in a recommendation for a lower dose: 60 mg in the first hour and a cumulative dose of 100 rngn8
The dose of 150 mg used in the TAM1 trial achieved a high proportion of infarct vessel patency without inducing an unacceptable rate of serious bleeding episodes Although the overall transfusion rate and periaccess bleeding incidence was somewhat higher compared to other trials, all TAM1 patients underwent emergent angiography per protocol, with a significant proportion (21%) undergoing coronary artery bypass surgery. Nearly all of these patients received transfusion First-hour dose: The dose of t-PA in the first hour appears to be a critical determinant of the time of recanalization. As previously demonstrated by TIM1 with baseline angiography, increasing the dose from 50 to 90 mg did not yield significantly higher patency at 90 minutes of therapy, but the speed of achieving reperfusion was markedly enhanced.7 In the current trial, the higher first-hour dose used in group B was associated with more rapid recanalization and a trend 01 % STENOSIS OF INFARCT RELATED ARTERY FIGURE 2. Infarct-related artery percent dlameter stenosis for group A versus group B patients at the final angiogram obtained during the acute study. A comparison of group A with group B patients shows an overall higher grade residual stenosis for group A. TIME AFTER t-PA INITIATION (hrs) FIGURE 3. Plasma fibrinogen levels (sulfite precipitation method)12 versus time after tissue plasminogen activator (t-PA) therapy. There were no significant differences between the 2 dose groups for nadir fibrinogen values.
toward a higher proportion of infarct vessel patency at the final angiogram. Weight adjustment: The results of this study further confirm the importance of a weight-adjusted dose of t-PA. In previous studies by Tap01 et all4 and Gold and co-workers,6J5 the utility of a weight-adjusted dose and its increased safety have been demonstrated. Even though a higher dose was employed in TAMI's group B patients, an overall decreased bleeding complication rate resulted which likely reflects weight adjustment. Patients weighing <90 kg had a definite increased risk of bleeding complications compared with heavier patients. In contrast, with a higher weightadjusted first-hour dose of t-PA, there was an increase in rate and proportion of infarct vessel patency. Thus, in order to avoid bleeding episodes and a high transfusion requirement, patients weighing <60 kg should probably receive a lower than 60 mg first-hour dose of t-PA. Group B data suggest that patients weighing up to 90 kg derive benefit from the higher dose in terms of coronary recanalization. Because doses >90 mg were not given in the first hour, the relative effects of throm. bolysis versus hemorrhage remain speculative in patients >90 kg.
Maintenance infusion: As demonstrated by Gold et a1,6 the purpose of the maintenance infusion is to increase the extent of coronary thrombolysis and limit rethrombosis. The ideal length and dose requirement of such a prolonged infusion have not yet been determined. In 1 recept study, too long an infusion has been reported to yield a high rate of periaccess bleeding that may be unacceptable? whereas in a receqt multicenter trial with a predominant Z-chain form of t*PA, up to a %hr low-dose infusion has been tested with apparent low reocclusion and bleeding rate compliqation. 17 In the current trial, a possible explanation for the increased bleeding observed in patients from group A is the lack of weight adjustment and the duration of maintenance infusion for 7 rather than 5 hours [group B). The additional 2 hours of maintenance infusion may be significant, as reflected by the 3-fold increase in gastrointestinal bleeding in group A, most of which was initially manifest during the infusion. The increased bleeding with longer maintenance infusions may reflect sustained fibrinolytic action of t-PA, Although the half-life of this trPA preparation is <3 miautes,5 the beta phase half-life is more than 20 minutes18 and this ongoing fibrinolysis proceeds despite physio? logic plasma levels of t-PA.lg It would therefore be anticipated that in group A patients there was a coqsiderably longer pharmaoologic fibrinolytic effect. Because reocclusion was actually not increased in group B patients, our data suggest that a shorter maintenance infusion of 5 hours may be preferable to 7 hours in achieving the purpose of limiting rethroqbosis without promoting bleeding.
Effects of dose on angioplasty success rate: A trend toward a higher success rate in acute coronary angioplasty was observed among group B patients, along with a decrease in the need for emergency bypass surgery. Althovgh this observation may theoretically * Regression analysis has shown that lighter weight, independent of female sex, was associated with increased bleeding risk." t Major bleeding refers to observed blood lass >I50 ml. t Continuous variables were analyzed using the Wilcoxon rank-surp test. Hct = hematocrit; U PRBC = units of packed red blood cells.
be attributed to enhanced coronary thrombolysis (with facilitation of the dilatation procedure], it also may be related to a learning curve phenomenon during the TAM1 trial. This point brings up the chief limitation of the current study: although a relatively large sample size at each of the 2 dose schedules was studied, this was a consecutive series and not a randomized comparison. Selection of patients for randomization to angioplasty was determined by the investigators. Duriqg the course of the trial, a trend toward decreased randomization to angioplasty and less need for emergency bypass surgery was noted, so that it remains unclear whether the dose change actually served as a pivotal factor for angioplasty: success.zo
